Message Image  

Blogs

Immune Monitor - March 2023

By SITC Communications posted 03-23-2023 00:00

  

A Message from the President

Dear Colleagues,

With humility and deep admiration, my letter to you, my SITC family, is in honor of the legacy of Dr. Pedro J. Romero, who is stepping down as Editor-in-Chief of the Journal for ImmunoTherapy of Cancer (JITC). Dr. Romero has served SITC and JITC with incredible dedication, care, and strategically insightful direction as our founding Editor-in-Chief from the journal’s conception, to its launch, and through its meteoric rise. It goes without saying that our community owes a great deal of gratitude to Dr. Romero for growing JITC into the globally recognized scholarly journal that it is today.

I had the honor of working with Dr. Romero on the journal as a Section Editor for several years, and directly bore witness to his commendable leadership, gracious attitude, and steadfast strategic vision. During Dr. Romero’s decade at the helm of JITC, he shepherded over 2,400 manuscripts to publication, accumulated more than 40,000 citations, enlisted north of 2,500 unique reviewers and led 170 leaders from 16 countries, elevating a relatively small, online, open access publication to one that has achieved great success. 

Three years ago, SITC created the annual Pedro J. Romero Service to JITC Award in honor of Dr. Romero’s unprecedented leadership, which recognizes an individual who has made significant contributions and demonstrated outstanding commitment to JITC. Nominations for this award along with SITC’s other Annual Awards are now being collected through May 1. Please help us build upon his great name by recognizing influential supporters of the journal.

To learn more about what’s next for the journal, including the announcement of Dr. James L. Gulley assuming the role of Interim Editor-in-Chief, I encourage you to read last week’s JITC Digest featuring a special message from Dr. Romero. 

With deep gratitude, we thank Dr. Romero again for all his contributions over the years! The SITC family simply can’t thank him enough.

Sincerely, 

Emens
Leisha Emens, MD, PhD
SITC President

 

Remembering Dr. Brian Olson

SITC honors the memory of member, Brian Olson, who passed away on March 10, 2023. Dr. Olson first joined SITC in 2011 and volunteered his time as a JITC reviewer and committee member.
SITC offers sincere condolences to his family for their loss. Dr. Olson will be missed by his friends and colleagues in the cancer immunotherapy community.
Read more about Dr. Olson here.



Please contact the SITC membership team at membership@sitcancer.org if you are aware of a SITC member who has passed away.

Brian Olson

The Latest at SITC

SPARKATHON 2023 
TOXICITIES IN CANCER IMMUNOTHERAPY

Join an exclusive program that brings together early career investigators with established leaders in cancer immunotherapy to foster leadership development, collaborations and scientific exchange.

FUNDING VIA FELLOWSHIPS

Do you know someone looking for immunotherapy research funding? SITC is offering six fellowships totaling $640,000 in funding. Get started on your application today or share these significant opportunities with the young investigators in your network.

WOMEN IN CANCER IMMUNOTHERAPY NETWORK (WIN) LEADERSHIP INSTITUTE

WIN seeks to promote and elevate women in the cancer immunotherapy field. The WIN Leadership Institute will feature presentations from experienced female leaders, panel discussions allowing participants to ask questions and interact with these leaders and our distinguished program organizers, and networking opportunities.

It's our 10th year of ACI programming! Join us for 15 topic-driven programs, completely free of charge for clinicians. Plus, these programs offer CME, CNE, CPE and MOC credit at no cost.

ADVANCES IN CANCER IMMUNOTHERAPY™

IMMUNOPREVENTION VIRTUAL SUMMIT

The SITC Immunoprevention Virtual Summit will highlight the opportunities and limitations in cancer interception and immunoprevention and serve as a platform to advocate for the widespread need for preventative methods and research. This open-door virtual educational event will present the state of the field and include participation of the stakeholders involved in this research including funding agencies, academic researchers, the FDA, and industry.

JOURNAL FOR IMMUNOTHERAPY OF CANCER

Check out the history of the journal and the many accomplishments of Dr. Romero by clicking the 10th anniversary logo to the left. Additionally, Dr. Romero created dedicated, special series to provide the latest on fresh, upcoming science. Discover the series and more JITC articles here:

WHAT'S NEW ON CONNECTED

Sign up or login to your free SITC account today to access free online immunotherapy education; like our Advances in Cancer Immunotherapy™: A Focus on Toxicity Management course. This course is interactive and provides information on incidence, onset, severity, and grading of immune-related toxicities and irAEs with immune checkpoint inhibitors.

MEDSCAPE

The new Medscape activity on immunotherapy allows clinicians to understand the role of immunotherapy for the management of early-stage solid tumors and how to best care for patients with these cancer types in clinical practice. Gain increased knowledge regarding clinical trial data and patient care while earning CME/ ABIM MOC credits.

Career Connections

SITC CAREER CONNECTIONS

Permalink